Lexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmA

Key Points

• Compagnie Lombard Odier SCmA increased its stake in Lexicon Pharmaceuticals by 200%, owning 330,000 shares worth approximately $312,000 by the end of the last quarter.
• Equities analysts have rated Lexicon Pharmaceuticals with an average of "Moderate Buy" and set an average target price of $3.23 per share.
• Lexicon Pharmaceuticals reported earnings of $0.01 per share, exceeding expectations, while revenue reached $28.87 million against a forecast of $4.87 million.

Compagnie Lombard Odier SCmA boosted its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 200.0% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 330,000 shares of the biopharmaceutical company's stock after purchasing an additional 220,000 shares during the period. Compagnie Lombard Odier SCmA owned approximately 0.09% of Lexicon Pharmaceuticals worth $312,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of LXRX. Straight Path Wealth Management purchased a new stake in shares of Lexicon Pharmaceuticals in the first quarter worth about $29,000. Wealth Enhancement Advisory Services LLC acquired a new position in Lexicon Pharmaceuticals in the first quarter valued at approximately $32,000. CWM LLC boosted its position in Lexicon Pharmaceuticals by 9,228.4% in the 1st quarter. CWM LLC now owns 105,504 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 104,373 shares in the last quarter. Cerity Partners LLC boosted its position in Lexicon Pharmaceuticals by 76.5% in the 1st quarter. Cerity Partners LLC now owns 170,387 shares of the biopharmaceutical company's stock worth $79,000 after purchasing an additional 73,875 shares in the last quarter. Finally, Ieq Capital LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $82,000. Institutional investors and hedge funds own 74.70% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on LXRX shares. HC Wainwright reiterated a "buy" rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research note on Tuesday, September 2nd. Citigroup lifted their price objective on shares of Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the company a "buy" rating in a report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $3.23.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX stock opened at $1.21 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.16 and a quick ratio of 4.16. The company has a market capitalization of $439.71 million, a PE ratio of -3.67 and a beta of 1.26. The firm's 50-day moving average is $1.14 and its two-hundred day moving average is $0.81. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.28 and a 12 month high of $2.18.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. The business had revenue of $28.87 million during the quarter, compared to analysts' expectations of $4.87 million. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative return on equity of 83.63%. Analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.